News
A new addition to our NGAL portfolio: Anti-NGAL (mouse) antibody pair
August 18 2008
Rat NGAL ELISA launched
June 27 2008
AACC 2008 Annual Meeting, 27-31 July 2008, Washington DC,
June 09 2008
INTERLEC-23 11-16 July 2008, Scotland
June 04 2008
An important addition to our complement antibody collection: Anti-C5b-9 (human) antibody
May 27 2008
New tools for cancer research: Plasminogen Activation System anti-bodies
May 05 2008
Product launch - Anti-NGAL (monkey) antibody
April 10 2008
The Biomarker World Congress 2008, 19-21 May - Philadelphia, USA
April 10 2008
ISICEM, Brussels, Belgium 18-21 March 2008
March 04 2008
BioPorto at ToxExpo, Seattle, Washington 16-20 March 2008
February 13 2008
New tools for cancer research: Plasminogen Activation System anti-bodies
May 05 2008 by Elaine Antonnette Lundberg
BioPorto Diagnostics is happy to announce the launch of a unique group of monoclonal antibodies against components of the Plasminogen Activation System. The antibodies are very well characterized and have been applied in numerous publications.
Plasminogen activator inhibitor-1 (PAI-1) antibody
PAI-1 is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). Current research is focused on determining the role of PAI-1 in various cancers
MON I-1, MON I-2, MON I-3, MON I-5, MON I-6
Tissue plasminogen activator (tPA) antibody
tPA converts plasminogen to active plasmin. It plays a key role in thrombolysis, several neurobiological processes and is also thought to play a role in cancer.
MON T-1
Urokinase plasminogen activator (uPA) antibody
uPA converts plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development.
MON U-5, MON U-6, MON U-12, MON U-16
Urokinase plasminogen activator receptor (uPAR) antibody
uPAR binds uPA and enhances and localizes uPA catalyzed plasminogen activation, and thereby plays a key role in cancer invasion and in several tissue remodelling processes. In addition uPAR also binds to vitronectin and therefore ongoing research to determine the biological functions independent of its role in uPA mediated proteolysis is advancing.
MON R-3, MON R-4, MON R-5
